Skip to main content
FATE THERAPEUTICS INC logo

FATE THERAPEUTICS INC — Investor Relations & Filings

Ticker · FATE ISIN · US31189P1021 LEI · 549300L14Q4UHOODLA90 US Manufacturing
Open in API
Filings indexed 811 across all filing types
Latest filing 2026-06-04 Report Publication Anno…
Country US United States of America
Listing US FATE

About FATE THERAPEUTICS INC

https://fatetherapeutics.com/

Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and autoimmune disorders. The company utilizes its proprietary induced pluripotent stem cell (iPSC) product platform to create master iPSC lines for the mass production of universal, off-the-shelf cell products. These multiplexed-engineered cell candidates are designed with novel synthetic controls to deliver multiple therapeutic mechanisms. This approach aims to overcome key limitations inherent to other cell therapies, with the goal of making treatments more effective, routine, and accessible for patients with life-threatening diseases.

Recent filings

Filing Released Lang Actions
8-K
Report Publication Announcement Classification · 85% confidence The document is a brief Form 8-K (under 5,000 characters) announcing that an updated corporate presentation is attached as an exhibit. It does not contain the presentation content itself, but merely reports its publication. Under the “menu vs meal” rule, this is an announcement of the report’s release rather than the report itself, so it should be classified as a Report Publication Announcement (RPA).
2026-06-04 English
10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8‐K current report under Item 2.02 “Results of Operations and Financial Condition,” which attaches a press release announcing the quarter ended March 31, 2026 financial results. It does not contain full financial statements (so it is not an Interim Report) but rather furnishes an earnings press release. This matches the Earnings Release category. Q1 2026
2026-05-13 English
DEF 14A - FATE THERAPEUTICS INC (0001434316) (Filer)
Proxy Solicitation & Information Statement
2026-04-24 English
10-K - FATE THERAPEUTICS INC (0001434316) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its financial results for the quarter and year ended December 31, 2025, and that the press release is attached as Exhibit 99.1. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3558 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and states that a report or press release is attached or published, it should be classified as a Regulatory Filing (RNS) rather than the report itself (like an Earnings Release or Annual Report). Therefore, this document is best classified as a Regulatory Filing (RNS).
2026-02-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.